



# FIG. 1A




REPLACEMENT SHEET

**FIG. 1B**




# FIG. 2




REPLACEMENT SHEET

**FIG. 3**




**REPLACEMENT SHEET**

**FIG. 4**




REPLACEMENT SHEET

**FIG. 5**




# FIG. 6




REPLACEMENT SHEET

# FIG. 7



# FIG. 8



REPLACEMENT SHEET



# FIG. 9

MAGE-3 /// CCTCCCCAGAGTCTCAGGGAGCCTCCAGCCTcCCCCACTACCATgAACTaCccCTCtctgGAGcCAAtCCTaTGAGGacTCCAGCAaCCaaGAAGAGGAGG  
 MAGE-2 // CCTCCCCAcAGTCTCAGGGAGCCTCCAGCTTctCGACTACCATCAACTaCACTCtcttggGAGaCAAtCCgaTGAGGGcTCCAGCAaCCaaGAAGAGGAGG  
 MAGE-1 / CCTCCCCAGAGTCTCAGGGAGCCTCCGCCtTTTCCCACTACTACCATCAACTtCActCTGAGAGAGGCAACCCAGTGAGGGTtTCCAGAGCCCGTGAAGAGGAGG  
 225 CHO-8  
 /// GGCCAAGCACCTTcccTgaCC-TGGAGTCCgaGTTCaAGCAGcAcTCAGTAgGAAGGTGGCCcGAGTtTGGTtCaTTTTTCTGTCTCTCAAGTATCGAGGCCA  
 // GGCCAAGaAtgtTtTcccgaCCcTGGAGTCCGAGTtTCCaAGCAGcAAATCAGTAgGAAGaTGGtTGAGTtTGGTtCaTTTTTCTGTCTCTCAAGTATCGAGGCCA  
 / GGCCAAGCAcCTCTCTGTATCC-TGGAGTCCtTGTtTCCGAGCAGTAATCACTAAAGAGGTGGCTGATtTGGTtGGTtTCTGTCTCTCAAAATATCGAGGCCA  
 325  
 /// GGGAGCCgGTCAAAAGGCAGAAATGCTGGgGAGTGTCTgTCg9AAATtTg9cAGcAAtTtCtTtTCTCTGTgATCTtTcAGCAAAAGCtTCCagTTCCTTGCAGCT  
 // GGGAGCCgGTCAAAAGGCAGAAATGCTGGAGAGTGTCTcTCAGAAATtTgCcAGgACTtCtTtTCCcGtGATCTtCaGCAAAAGCCTCcGAGTAcTtTGCAGCT  
 / GGGAGCCAGTCAAAAGGCAGAAATGCTGGAGAGTGTCTATCAAAATtTACAAAGCACTGTtTtTCTCTGAGATCTtTCCGGCAAAAGCCTCTGAGTCCtTtTGCAGCT  
 425 SEQ-4  
 /// GGTCTtTtTGGCATcGAGcTGAtGGAAAGtGgACCCCAcCGGCCACTtGtTAcATCtTtTgCcCACCTGCCTgGGcCTCTCTACGATGGCCCTGCTGGGTGAcAAT  
 // GGTCTtTtTGGCATcGAGGTGgtGGAAAGtGtCCCCAtCaGCCACTtGtTAcATCCTTGTCACTGCCTgGGcCTCTCTCTACGATGGCCCTGCTGGGcGAcAAT  
 / GGTCTtTtTGGCATtGAGTGAAGGAAGCAgACCCcACCGGCCACTCTCTATGTCTCTGTCTACCTtGCCtTAGGTCTCTCTCTATGATGGCCCTGCTGGGTGATAAT  
 525  
 /// CAGATCATGCCCCAAGgCAGGCCcTCCTGATATAATcGTCTTGGcCATAATcGCAAgagAGGGCGGAcTgTGCCcCTTGAGGAGaAAATCTGGGAGGAGCTGAGTG  
 // CAGgTCATGCCCCAAGACAGGCCcTCCTGATATAATcGTC-TGGcCATAATcGCATATaGAGGGCGGAcTgTGCCcCTTGAGGAGaAAATCTGGGAGGAGCTGAGTa  
 / CAGATCATGCCCCAAGACAGGCCtTCTCTGATATAATtGTCTTGGTcATGATtTGCAATGGAGGGCGGCCATGTCTCTTGAGGAGAAATCTGGGAGGAGCTGAGTG  
 625 CHO-9


REPLACEMENT SHEET

$\beta$ -action


MAGE

PROBES

FIG. 10




MZ2-MEL.3.0  
MZ2-MEL 1982  
MZ2-MEL.2.2 E-  
MZ2-PBL-PHA  
Lung  
Kidney




MZ2-MEL 3.0  
MZ2-CTL 82/30  
LB34-MEL  
LB17-MEL  
MI665/2-MEL  
LB41-MEL  
MI10221-MEL  
MI13443-MEL  
SK23-MEL  
SK33-MEL

Other  
melanomas



LB4-MEL  
MI4024-MEL  
MZ3-MEL  
MZ5-MEL  
SK29-MEL  
LB31-COL  
LS411-COL

Other  
tumors



H209-SCLC  
H345-SCLC  
H510-SCLC  
TT

REPLACEMENT SHEET

# FIG. 11A

	EXPRESSION OF MAGE GENE FAMILY					RECOGNITION BY ANI-E CTL	
	Northern blot probed with cross-reactive MAGE-1 probe*	cDNA-PCR product probed with oligonucleotide specific for:			tested by: TNF release†	Lysis§	Expression of antigen MZ2-E after transfection**
		MAGE-1	MAGE-2	MAGE-3†			
Cells of patient MZ2	melanoma cell line MZ2-MEL.3.0	+++	+++	+++	+	+	
	tumor sample MZ2 (1982)	+++	+++	+++			
	antigen-loss variant MZ2-MEL.2.2	-	+++	+++	-	-	
	CTL clone MZ2-CTL.82/30	-	-	-			
	PHA-activated blood lymphocytes	-	-	-			
Normal tissues	Liver	-	-	-			
	Muscle	-	-	-			
	Skin	-	-	-			
	Lung	-	-	-			
	Brain	-	-	-			
	Kidney	-	-	-			
Melanoma cell lines of HLA-A1 patients	LB34-MEL	++	+++	+++	+	+	+
	MI665/2-MEL	-	-	-	-	-	+
	MI10221-MEL	-	++	+++	-	-	+
	MI13443-MEL	+++	+++	+++	+	+	-
	SK33-MEL	-	+++	+++	-	-	+
	SK23-MEL	-	+++	+++	-	-	

\* Data obtained in the conditions of figure 5.

† Data obtained as described in figure 6.

‡ TNF release by CTL 82/30 after stimulation with the tumor cells as described in (11).

§ Lysis of 51 Cr labelled target by CTL 82/30 in the conditions of figure 1.

\*\* Cells transfected with the 2.4 kb fragment of gene MAGE-1 were tested for their ability to stimulate TNF release by CTL 82/30

# FIG. 11B

	EXPRESSION OF MAGE GENE FAMILY				RECOGNITION BY ANI-E CTL	
	Northern blot probed with cross-reactive MAGE-1 probe*	cDNA-PCR product probed with oligonucleotide specific for:			tested by: TNF release†	Lysis§ Expression of antigen MZ2-E after transfection**
		MAGE-1	MAGE-2	MAGE-3†		
Melanoma cell lines of other patients	LB17-MEL	+	+++	+++	-	-
	LB33-MEL	+	+++	+++	-	-
	LB4-MEL	-	-	-	-	-
	LB41-MEL	-	-	-	-	-
	MI4024-MEL	+	+++	+++	-	-
	SK29-MEL	-	-	-	-	-
Melanoma tumor sample	MZ3-MEL	+	+++	+++	-	-
	MZ5-MEL	+	+++	+++	-	-
	BB5-MEL	+	+++	+++	-	-
		+	++	+++	-	-
Other tumor cell lines	small cell lung cancer H209	-	+++	+++	-	-
	small cell lung cancer H345	-	+++	+++	-	-
	small cell lung cancer H510	-	+++	+++	-	-
	small cell lung cancer LB11	+	+++	+++	-	-
	bronchial squamous cell carcinoma LB37	-	-	+++	-	-
	thyroid medullary carcinoma TT	+++	+++	+++	-	-
	colon carcinoma LB31	-	+++	+++	-	-
	colon carcinoma LS411	-	-	-	-	-
Other tumor samples	chronic myeloid leukemia LLC5	-	-	-	-	-
	acute myeloid leukemia TA	-	-	-	-	-

\* Data obtained in the conditions of figure 5.


† Data obtained as described in figure 6.

‡ TNF release by CTL 82/30 after stimulation with the tumor cells as described in (11).

§ Lysis of 51 Cr labelled target by CTL 82/30 in the conditions of figure 1.

\*\* Cells transfected with the 2.4 kb fragment of gene MAGE-1 were tested for their ability to stimulate TNF release by CTL 82/30

**FIG. 12**



REPLACEMENT SHEET

mage 1 1

mage 2 65

mage 3 2400

mage 21 797

mage 31 760

mage 4 11

mage 5 67

mage 6 111

mage 7 1011

mage 8 1550

## REPLACEMENT SHEET